IP Verse

Use Of Aminopyridine, In Particular Amirampridine, In The Treatment Of Virally Associated Fatigue - EP4349333

The patent EP4349333 was granted to Bhmeke on Oct 30, 2024. The application was originally filed on Jul 28, 2023 under application number EP23188553A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4349333

BHMEKE
Application Number
EP23188553A
Filing Date
Jul 28, 2023
Status
Granted And Under Opposition
Sep 27, 2024
Grant Date
Oct 30, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

LANGEJul 29, 2025HERTIN UND PARTNER RECHTS UND PATENTANWALTE PARTG MBBADMISSIBLE

Patent Citations (4) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0159112
DESCRIPTIONEP3696169
DESCRIPTIONUS2004106651
OPPOSITIONUS2004106651

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- SHIEH, PERRYSHARMA, KHEMA, KOHRMAN, BRUCEOH, SHIN J, "Amifampridine Phosphate (Firdapse) Is Effective in a Confirmatory Phase 3 Clinical Trial in LEMS", Clinical Trial J Clin Neuromuscul Dis, (20190300), vol. 20, no. 3, pages 111 - 119-
EXAMINATION- THOMAS BOEHMEKE, "Reduced Fatigue Symptoms in the Post-COVID Syndrome With Amifampridine: A Collective Casuistry With Double-Blind Discontinuation Trials", CUREUS, US, doi:10.7759/cureus.52935, ISSN 2168-8184, (20240125), URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10893954/pdf/cureus-0016-00000052935.pdf, XP093155121
OPPOSITION- Informationsblatt zu Firdapse (Amifampridin) der EMA (summary of product characteristics) (no date found)-
OPPOSITION- Sheean G., Murray Nicholas M F, Rothwell John C, Miller David H, Thompson Alan J, "An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis", Brain, (19980501), vol. 121, no. 5, doi:10.1093/brain/121.5.967, pages 967 - 975, XP093036446
OPPOSITION- Mainero C., Inghilleri M., Pantano P., Conte A., Lenzi D., Frasca V., Bozzao L., Pozzilli C., "Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine", Neurology, Lippincott Williams & Wilkins, (20040608), vol. 62, no. 11, doi:10.1212/01.WNL.0000129263.14219.A8, ISSN 0028-3878, pages 2044 - 2050, XP093300690
SEARCH- SHEEAN G. ET AL, "An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis", BRAIN, (19980501), vol. 121, no. 5, doi:10.1093/brain/121.5.967, pages 967 - 975, XP093036446 [X] 1,6,14,15 * abstract * [Y] 1-15 [I] 7-13
SEARCH- JOLI JIAN ET AL, "Post-COVID-19 fatigue: A systematic review", FRONTIERS IN PSYCHIATRY, (20220811), vol. 13, doi:10.3389/fpsyt.2022.947973, ISSN 1664-0640, XP093112425 [Y] 1-15 * Kapitel Therapeutic approaches *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents